Mlenny Cellectis ( NASDAQ: CLLS ) said it has received orphan drug designation from EU regulators for its allogeneic CAR-T product candidate UCART22 for the treatment of acute lymphoblastic leukemia, or ALL. The company expects to report updates on its Phase 1/2 BALLI-01 study for the product by the end of the year. More on Cellectis Cellectis S.
A. (CLLS) Q1 2024 Earnings Call Transcript Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024 AstraZeneca invests $140M in Cellectis, raising stake to 44% Seeking Alpha’s Quant Rating on Cellectis Historical earnings data for Cellectis.
